EP0608111B1 - Isolation and structure of spongistatin 1 and its use as an anti-tumor agent - Google Patents

Isolation and structure of spongistatin 1 and its use as an anti-tumor agent Download PDF

Info

Publication number
EP0608111B1
EP0608111B1 EP94300362A EP94300362A EP0608111B1 EP 0608111 B1 EP0608111 B1 EP 0608111B1 EP 94300362 A EP94300362 A EP 94300362A EP 94300362 A EP94300362 A EP 94300362A EP 0608111 B1 EP0608111 B1 EP 0608111B1
Authority
EP
European Patent Office
Prior art keywords
brs
brd
spongistatin
brt
ddd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP94300362A
Other languages
German (de)
French (fr)
Other versions
EP0608111A1 (en
Inventor
George R. Pettit
Cherry L. Herald
Zbigniew A. Cichacz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizona Board of Regents of University of Arizona
University of Arizona
Original Assignee
Arizona Board of Regents of University of Arizona
University of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizona Board of Regents of University of Arizona, University of Arizona filed Critical Arizona Board of Regents of University of Arizona
Publication of EP0608111A1 publication Critical patent/EP0608111A1/en
Application granted granted Critical
Publication of EP0608111B1 publication Critical patent/EP0608111B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C12P19/445—The saccharide radical is condensed with a heterocyclic radical, e.g. everninomycin, papulacandin

Definitions

  • the present invention relates to the discovery and isolation of new and extremely potent constituent of an Eastern Indian Ocean marine sponge of the genes Spongia herein denominated "spongistatin 1".
  • This new perhydropyran-containing structure was found to be remarkably potent and specific against twenty human cancer cell lines in the U.S. National Cancer Institute's panel.
  • NCI National Cancer Institute
  • J. Org. Chem. (1993) 58, 1302-1304 was published after the priority date of the present application. It relates to the isolation and structure of spongistatin 1 from an Eastern Indian Ocean Sponge.
  • EP-A-0,264,173 (Arizona Board of Regents) relates to several Bryostatins isolated from Bugula neritina which exhibit potent antineoplastic activity.
  • Spongistatin 1 has the following structure:
  • the principal object of the present invention is the isolation of a structurally unprecedented macrocyclic lactone herein denominated "spongistatin 1" having a log molar TGI 50 of about ⁇ -10 against various human cancer cell lines.
  • Another object of the present invention is the structural elucidation of the substance denominated "spongistatin 1".
  • Spongistatin 1 was found to be incredibly active and selective against twenty (CCRF-CEM, HL-60, SR leukemias; NCI-H226, NCI H23, NCI H460, NCI H522 non-small cell lung; DMS 114, and 273 small cell lung; Colo 205, DCC-2998, HCT-116, RT29, KM 2022 colon; SF-239.
  • U-251 CNS; SK-MEL-5 melanoma; OVCAR-3 and -8 ovarian; and A-498 renal cancers of the NCI panel of sixty human cancer cell lines with log molar TGI 50 ranging from -8.98 to ⁇ -10.00.

Abstract

An Eastern Indian Ocean marine sponge in the genus Spongia was located in the Republic of the Maldives and found to contain a structurally unprecedented macrocyclic lactone named spongistatin 1. The new perhydropyran-containing structure, as shown below, was found to be remarkably potent and specific, log molar TCI50 to < -10, against twenty human cancer cell lines in the U.S. National Cancer Institute's panel of sixty. <CHEM>

Description

The present invention relates to the discovery and isolation of new and extremely potent constituent of an Eastern Indian Ocean marine sponge of the genes Spongia herein denominated "spongistatin 1". This new perhydropyran-containing structure was found to be remarkably potent and specific against twenty human cancer cell lines in the U.S. National Cancer Institute's panel.
A great number of ancient marine invertebrate species in the Phyla Bryozoa, Mollusca and Porifera were well established in the earth's oceans over one billion years ago. Certainly such organisms had explored trillions of biosynthetic reactions in their evolutionary chemistry to reach present levels of cellular organization, regulation and defense. Marine sponges have changed minimally in physical appearance for nearly 500 million years, suggesting a very effective chemical evolution in response to changing environmental conditions for at least that time period. Some recognition of the potential for utilizing biologically potent marine animal constituents was recorded in Egypt about 2,700 BC, and by 200 BC sea hare extracts were being used in Greece for medicinal purposes. Such considerations, combined with the general observation that marine organisms (especially invertebrates and sharks) rarely develop cancer, led to the first systematic investigation of marine animal and plant anticancer constituents.
By 1968 ample evidence had been obtained, based on the U. S. National Cancer Institute's key experimental cancer systems, that certain marine organisms would provide new and structurally novel antineoplastic and/or cytotoxic agents. Analogous considerations suggested that marine organisms could also provide effective new drugs for other severe medical challenges, such as viral diseases. Furthermore, marine organisms were expected to contain potentially useful drug candidates (and biochemical probes) of unprecedented structural types, that would have eluded discovery by contemporary techniques of medicinal chemistry. Fortunately, some of these expectations have been realized in the intervening period. Illustrative of these successes are the discoveries of the bryostatins, dolastatins, and cephalostatins by the Cancer Research Institute in Tempe, Arizona where several members of these series of remarkable anticancer drug candidates are either now in human clinical trial or preclinical development. See U.S. Patent Nos. 4,816,444, 4,833,257, 4,873,245, and 4,879,278.
As is well known to those presently engaged in medical research, the time between the isolation of a new compound, and its introduction to the market place takes at least several years in the best case and can take several decades. Consequently, industry, in association with the government, has devised a number of qualifying tests which serve two purposes. One purpose is to eliminate those substances whose results in the qualifiers unequivocally demonstrate that the further expenditure of funds on developing those substances would be economically counter-productive. The second, and more important purpose, is to identify those substances which demonstrate a high likelihood of success and therefore warrant the requisite further investment necessary to obtain the data which is required to meet the various regulatory requirements imposed by those governments which regulate the market place into which such substances will enter.
The present cost of obtaining such data approaches Ten Million Dollars ($10,000,000 U.S.) per substance. Economics dictate that such an investment not be made unless there is a reasonable likelihood that it can be recovered. Absent such an opportunity, there will be no such investment, and without investment, the research requisite for the discovery of potentially life saving drugs will stop.
Only two hundred years ago, many diseases ravaged humankind. Many of these diseases now have been controlled or eradicated. In the development of the means to treat or control these diseases, work with the appropriate common experimental animals was of critical importance. With the various types of cancers, and with the HIV virus, such work is presently ongoing. The research for the treatment of various types of cancer is coordinated in the United States by the National Cancer Institute (NCI). NCI, as a government entity, has been charged with assisting anti-cancer research. To establish whether a substance has anti cancer activity, NCI has established a variety of protocols, one of which involves testing the candidate substance against a cell line panel containing 60 human tumor cell lines. This protocol has been verified and is generally accepted throughout the scientific community. This protocol and the established statistical means of evaluating the results obtained therefrom have been fully described in the literature. See Principles & Practice of Oncology PPO Updates, Volume 3, Number 10, October 1989, by Michael R. Boyd, M.D., Ph.D., for an indepth description of the test protocol. The statistical analysis is explained in "Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Means Graph and COMPARE Algorithm" Journal of the National Cancer Institute Reports Vol. 81, No. 14, Pg. 1088, July 14, 1989, by K.D. Paull et al. Both of these references are incorporated herein by this reference thereto.
The Constitution of the United States (Art. 1, Sec. 8) authorizes Congress to establish the United States Patent and Trademark Office (USPTO) to promote scientific advancement. This obligation can only be fully met when the USPTO accepts current medical and scientific realities in the area of medical research.
J. Org. Chem. (1993) 58, 1302-1304 was published after the priority date of the present application. It relates to the isolation and structure of spongistatin 1 from an Eastern Indian Ocean Sponge.
Tetrahedron Lett. (1993) 34, 2795-2798 was published after the priority date of the present application. It relates to the isolation and structure of Altohyrtin A from the Okinawan Marine Sponge Hyrtios altum.
Chem. Pharm. Bull. (1993) 41, 989-991 was published after the priority date of the present application. It relates to the isolation of Altohyrtins B and C and S-deacetyl Altohyrtin A from Hyrtios altum.
J. Chem. Soc., Chem. Commun. (1993) 1166-1168 was published after the priority date of the present application. It relates to the isolation and structure of Spongistatins 2 and 3 from an Eastern Indian Ocean Spongia species.
J. Am. Chem. Soc. (1993) 115, 3977-3981 was published after the priority date of the present application. It relates to Cinachyrolide A isolated from marine sponge Cinachyra species.
EP-A-0,264,173 (Arizona Board of Regents) relates to several Bryostatins isolated from Bugula neritina which exhibit potent antineoplastic activity.
Numerous compounds have been discovered which demonstrate significant antineoplastic activity. As discussed above, many of these compounds have been extracted, albeit with great difficulty, from living creatures such as the sponge or the sea hare.
However, once the isolation and testing of such compounds has progressed, a practical problem exists, namely, how to obtain a significant quantity of the compound.
Unlike cinchona bark which is collected to produce quinine and has an excellent yield, the collection and processing of the compounds of the present invention in the natural occurring state ranges from the grossly impractical to the utterly impossible. Even ignoring potential ecological effects, the population of such creatures is clearly insufficient. Accordingly, the elucidation of the absolute structure of such antineoplastic compounds is essential.
A major component of vigorous efforts for over two decades has been directed at marine sponge antineoplastic and/or cytotoxic biosynthetic products and it is toward the furtherance of that effort that the present invention is directed.
Marine Porifera in the genus Spongia (family Spongiidae, Class Demospongiae) have proved to be good sources of tetracyclic diterpenes. Based on previous investigations the Spongia would not seem a particularly attractive reservoir of antineoplastic macrocyclic lactones. But natural products are replete with surprises. We are very pleased to report discovery in a Spongia sp. a macrocyclic lactone designated spongistatin 1 that possesses a remarkable structure exhibiting phenomenally potent (and selective) activity against twenty of the U.S. national Cancer Institute's (NCI) panel of sixty human cancer cell lines.
A 1988 recollection (400 kg wet wt.) of the dark brown (to black) Spongia sp. from the Eastern Indian Ocean (Republic of the Maldives), was extracted with methanol followed by methylene chloride-methanol. A methylene chloride fraction derived from the combined extract was carefully separated (guided by P388 lymphocytic leukemia bioassay) employing an extensive series of LH-20 SEPHADEX (Registered Trade mark) gel permeation and partition (also on SILICA GEL) chromatographic procedures followed by final isolation using reversed phase (PREPEX 5-20µ, C8 column) high performance liquid chromatography with 5:5:7 acetonitrile-methanol-water as eluent to afford (13.8 mg, 5.1 10-4 yield) colorless spongistatin 1 as an amorphous powder, mp 161-162°C; [α]22D + 26.2° (c=0.32, CH3OH); UV (CH3OH) λmax 216 nm, e 8490; IR (film) 3430, 2928, 1736, 1383, 1232, 1177, 1085, 993 cm-1 and high resolution FAB MS, m/z 1245.5949 (M+Na]+ corresponding to C63H95ClO21Na (calcd. mass 1245.5952) with low resolution FAB peaks at m/z 1245.5 [M+Na]+ as parent peak and 1187.5 [M-35] representing loss of chlorine.
Spongistatin 1 has the following structure:
Figure 00080001
Accordingly, the principal object of the present invention is the isolation of a structurally unprecedented macrocyclic lactone herein denominated "spongistatin 1" having a log molar TGI50 of about <-10 against various human cancer cell lines.
Another object of the present invention is the structural elucidation of the substance denominated "spongistatin 1".
These and still further objects as shall hereinafter appear are readily fulfilled by the present invention in a remarkably unexpected manner as will be readily discerned from the following detailed description of an exemplary embodiment thereof.
Structural elucidation of spongistatin 1 was especially challenging and required three separate (and in-depth), high field 400 and 500 MHz 2D NMR analyses (APT, 1H-1H-COSY, 1H-13C-COSY, HMBC, and NOE) employing acetonitrile-d3, pyridine-d5 and methanol-d3 solvent systems. The assignments are recorded in Table 1. Results of a series of selective acetylation experiments assisted in deducing some of these assignments.
Spongistatin 1 was found to be incredibly active and selective against twenty (CCRF-CEM, HL-60, SR leukemias; NCI-H226, NCI H23, NCI H460, NCI H522 non-small cell lung; DMS 114, and 273 small cell lung; Colo 205, DCC-2998, HCT-116, RT29, KM 2022 colon; SF-239. U-251 CNS; SK-MEL-5 melanoma; OVCAR-3 and -8 ovarian; and A-498 renal cancers) of the NCI panel of sixty human cancer cell lines with log molar TGI50 ranging from -8.98 to < -10.00.
NMR assignments for spongistatin 1 recorded in CD3CN. Coupling constants are in Hz (in parenthesis). The mixing time for the HMBC was set at 130 microsecond).
13C(100 MHz) XHCorr. (400 MHz) HMBC(500 MHz, C to H)
1 173.07 H-2;H-41
2 40.86 2.44 dd(10,18) H-4
2.53 dd(2,18)
3 63.59 4.25 brt(10) H-2;H-8
4 34.65 1.55*;1.68 H-2;H-6
5 67.06 4.92 brs
6 38.17 1.67 dd(5,14); H-5;H-8
1.78 brd(14)
7 99.26 H-6;H-8;H-9a
8 46.76 1.47 d(14);1.60 H-9a;H-6
9 69.64 H-9a;OH(C9) ;H-8
9a 30.21 1.06 s H-8;H-10
10 44.96 1.28 ;1.55 H-9a;H-12;H-8
11 65.00 4.25 brt(10) H-12;H-13a;H-15;H-6
12 44.24 1.99*;2.27 brd(14) H-10;H-13a
13 148.03 H-12;H-13a;H-14a;
H-15
13a 114.86 4.83 brs;4.83 brs H-12;H-14
14 36.60 2.78 H-13a;H-14a;H-15;
H-16;H-12
14a 12.09 1.04 d(6.9) H-15
15 75.34 5.12 dd(1.7,11) H-13a;H-14a;H-16;
H-16a
16 47.62 3.04 dq(7,11) H-15;H-16a
16a 13.73 1.15 d(7) H-15;H-16
17 213.52 H-16;H-16a;H-18;
H-15
18 51.94 2.62 brd(18) H-16;H-20
2.86 dd(11,18)
19 66.16 4.00 brt(11) H-18
20 37.70 0.97 ddd(12,12,12); H-18;H-22
1.98
21 73.98 3.46 tt(4,4,12,12) H-22;H-OMe;H-20
22 44.18 1.08 t(12);1.99 H-21;H-20
23 99.91 H-18;H-22;H-24;H-27
24 34.91 1.55 ;2.28 H-22
25 64.41 3.93 brm H-26;H-27;H-24
26 39.11 1.57 ;1.57 H-28;H-24
27 61.22 5.00 ddd(4.3,10,10) H-26;H-29
28 131.22 5.32 brt(10) H-27;H-30
29 133.42 5.48 ddd(10,10,10) H-27;H-30
30 28.07 2.00 ;2.19 H-28;H-29;H-31;
H-32
31 27.04 1.23 ;1.60 H-29;H-33;H-30;H-32
32 32.82 1.30 m;1.42 m H-33
33 67.15 4.13 dt(3.4,3.4,8) H-34a
34 39.32 1.57 m H-34a;H-36
34a 11.55 0.81 d(7) H-33;H-34
35 71.47 3.65 brs H-34a;H-33;H-36
36 33.79 1.61 ;1.89 OH(C37);H-34
37 99.41 H - 3 3 ; H - 3 6 ;
OH(C37),H-38
38 73.11 3.34 brs H-36
39 81.30 3.72 brd(10) H-40a;H-41
40 37.26 1.91 H-40a;H-39;H-41
40a 12.69 0.74 d(7) H-40;H-41
41 80.60 4.75 dd(9,11) H-40a;H-39;H-40;
H-42;H-43
42 73.11 3.12 t(9) H-40;H-41;H-43;
H-40a
43 78.72 3.39 brt(9) H-39;H-41;H-42;H-44
44 40.24 2.08 ;2.76 brd(13) H-42;H-46;H-45a
45 144.00 H-45a;H-43;H-44;
H-46;H-47
45a 116.61 4.86 brs;4.89 brs H-44;H-46
46 43.93 2.33 brdd(7,14); H-44;H-45a
2.19
47 70.13 4.36 ddd(6,7,11) H-46;H-48
48 139.21 6.11 dd(6,15) H-46;H-47
49 126.99 6.41 brd(15) H-47;H-48;H-51
50 139.21 H-48;H-49;H-51
51 116.48 5.35 brs;5.45 brs H-48;H-49
OMe 55.72 3.24 s H-21
OAc 21.78 1.94 s
171.61 H-OAc(δ1.94);H-5
OAc 21.00 1.84 s
170.21 H-OAc(δ1.84);H-15
OH(C25) 4.39 d(9.9)
OH(C37) 4.73 d(2)
OH(C9) 4.32 brs
OH 3.83 brm

Claims (5)

  1. A compound denominated herein as spongistatin 1 and having the following structural formula:
    Figure 00120001
  2. A compound according to claim 1 and having, when recorded in CD3CD, the NMR assignments; 13C(100 MHz) XHCorr.(400 MHz) HMBC(500 MHz, C to H) 1 173.07 H-2;H-41 2 40.86 2.44 dd(10,18) H-4 2.53 dd(2,18) 3 63.59 4.25 brt(10) H-2;H-8 4 34.65 1.55 ;1.68 H-2;H-6 5 67.06 4.92 brs 6 38.17 1.67 dd(5,14); H-5;H-8 1.78 brd(14) 7 99.26 H-6;H-8;H-9a 8 46.76 1.47 d(14);1.60 H-9a;H-6 9 69.64 H-9a;OH(C9);H-8 9a 30.21 1.06 s H-8;H-10 10 44.96 1.28*;1.55 H-9a;H-12;H-8 11 65.00 4.25 brt(10) H-12;H-13a;H-15;H-6 12 44.24 1.99*;2.27 brd(14) H-10;H-13a 13 148.03 H-12;H-13a;H-14a; H-15 13a 114.86 4.83 brs;4.83 brs H-12;H-14 14 36.60 2.78 H-13a;H-14a;H-15; H-16;H-12 14a 12.09 1.04 d(6.9) H-15 15 75.34 5.12 dd(1.7,11) H-13a;H-14a;H-16; H-16a 16 47.62 3.04 dq(7,11) H-15;H-16a 16a 13.73 1.15 d(7) H-15;H-16 17 213.52 H-16;H-16a;H-18; H-15 18 51.94 2.62 brd(18) H-16;H-20 2.86 dd(11,18) 19 66.16 4.00 brt(11) H-18 20 37.70 0.97 ddd(12,12,12); H-18;H-22 1.98 21 73.98 3.46 tt(4,4,12,12) H-22;H-OMe;H-20 22 44.18 1.08 t(12);1.99 H-21;H-20 23 99.91 H-18;H-22;H-24; H-27 24 34.91 1.55 ;2.28 H-22 25 64.41 3.93 brm H-26;H-27;H-24 26 39.11 1.57*;1.57 H-28;H-24 27 61.22 5.00 ddd(4.3,10,10) H-26;H-29 28 131.22 5.32 brt(10) H-27;H-30 29 133.42 5.48 ddd(10,10,10) H-27;H-30 30 28.07 2.00 ;2.19 H-28;H-29;H-31; H-32 31 27.04 1.23 ;1.60 H-29;H-33;H-30;H-32 32 32.82 1.30 m;1.42 m H-33 33 67.15 4.13 dt(3.4,3.4,8) H-34a 34 39.32 1.57 m H-34a;H-36 34a 11.55 0.81 d(7) H-33;H-34 35 71.47 3.65 brs H-34a;H-33;H-36 36 33.79 1.61 ;1.89 OH(C37) ;H-34 37 99.41 H-33;H-36;OH (C37),H-38 38 73.11 3.34 brs H-36 39 81.30 3.72 brd(10) H-40a;H-41 40 37.26 1.91 H-40a;H-39;H-41 40a 12.69 0.74 d(7) H-40;H-41 41 80.60 4.75 dd(9,11) H-40a;H-39;H-40; H-42;H-43 42 73.11 3.12 t(9) H-40;H-41;H-43; H-40a 43 78.72 3.39 brt(9) H-39;H-41;H-42;H-44 44 40.24 2.08 ;2.76 brd(13) H-42;H-46;H-45a 45 144.00 H-45a;H-43;H-44; H-46;H-47 45a 116.61 4.86 brs;4.89 brs H-44;H-46 46 43.93 2.33 brdd(7,14); H-44;H-45a 2.19 47 70.13 4.36 ddd(6,7,11) H-46;H-48 48 139.21 6.11 dd(6,15) H-46;H-47 49 126.99 6.41 brd(15) H-47;H-48;H-51 50 139.21 H-48;H-49;H-51 51 116.48 5.35 brs;5.45 brs H-48;H-49 OMe 55.72 3.24 s H-21 OAc 21.78 1.94 s 171.61 H-OAc(δ1.94);H-5 OAc 21.00 1.84 s 170.21 H-OAc(δ1.84);H-15 OH(C25) 4.39 d(9.9) OH(C37) 4.73 d(2) OH(C9) 4.32 brs OH 3.83 brm
  3. A method for inhibiting the growth of human cancer cells which comprises administering to an in vitro environment containing such human cancer cells a pharmaceutically acceptable carrier combined with the compound of claim 1 in an amount effective to inhibit the growth of such human cancer cells in said environment.
  4. The use of a compound having the structural formula:
    Figure 00140001
    in medicine.
  5. The use of a compound having the structural formula:
    Figure 00150001
    in the manufacture of a medicament for inhibiting the growth of human cancer cells.
EP94300362A 1993-01-19 1994-01-19 Isolation and structure of spongistatin 1 and its use as an anti-tumor agent Expired - Lifetime EP0608111B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/006,270 US5436400A (en) 1993-01-19 1993-01-19 Isolation and structure of spongistatin 1
US6270 1995-11-07

Publications (2)

Publication Number Publication Date
EP0608111A1 EP0608111A1 (en) 1994-07-27
EP0608111B1 true EP0608111B1 (en) 1998-05-27

Family

ID=21720096

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94300362A Expired - Lifetime EP0608111B1 (en) 1993-01-19 1994-01-19 Isolation and structure of spongistatin 1 and its use as an anti-tumor agent

Country Status (8)

Country Link
US (1) US5436400A (en)
EP (1) EP0608111B1 (en)
JP (1) JPH072866A (en)
AT (1) ATE166652T1 (en)
CA (1) CA2113656C (en)
DE (1) DE69410492T2 (en)
DK (1) DK0608111T3 (en)
ES (1) ES2119077T3 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5393897A (en) * 1993-07-02 1995-02-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structure of spongistatins 5,7,8 and 9
WO1997048278A1 (en) * 1996-06-18 1997-12-24 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of The Arizona State University Antifungal activity of the spongistatins
US5883120A (en) * 1997-06-16 1999-03-16 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Antifungal activity of the spongistatins
US5952376A (en) * 1997-11-07 1999-09-14 The Trustees Of The University Of Pennsylvania Trienyl compounds
US6521661B1 (en) 2000-07-20 2003-02-18 Harbor Branch Oceanographic Institution, Inc. Cyclic peroxides as novel antifungal agents
WO2016130969A1 (en) 2015-02-13 2016-08-18 George Robert Pettit Silstatin compounds
US11629167B2 (en) 2017-11-09 2023-04-18 Arizona Board Of Regents On Behalf Of Arizona State University Betulastatin compounds
CN114605430B (en) * 2022-03-18 2023-09-05 中国科学院海洋研究所 Macrocyclic dilactone compound, and preparation method and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833257A (en) * 1986-07-28 1989-05-23 Arizona Board Of Regents Compositions of matter and methods of using same
US5196447A (en) * 1991-08-08 1993-03-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting On Behalf Of Arizona State University Neristatin 1

Also Published As

Publication number Publication date
ATE166652T1 (en) 1998-06-15
CA2113656A1 (en) 1994-07-20
CA2113656C (en) 2000-07-18
DE69410492T2 (en) 1998-11-05
ES2119077T3 (en) 1998-10-01
JPH072866A (en) 1995-01-06
DK0608111T3 (en) 1999-01-18
EP0608111A1 (en) 1994-07-27
DE69410492D1 (en) 1998-07-02
US5436400A (en) 1995-07-25

Similar Documents

Publication Publication Date Title
Pettit et al. Antineoplastic agents. 257. Isolation and structure of spongistatin 1
Nilanonta et al. Precursor-directed biosynthesis of beauvericin analogs by the insect pathogenic fungus Paecilomyces tenuipes BCC 1614
EP0634414B1 (en) Isolation and structure of spongistatins 5,7,8,and 9 and their use as antitumor agents
US5681847A (en) Methods of using discodermolide compounds
US5430053A (en) Isolation and structure of dictyostatin 1
EP0608111B1 (en) Isolation and structure of spongistatin 1 and its use as an anti-tumor agent
US5352804A (en) Isolation and structure of Halistatin 2
US5426194A (en) Isolation and structure of Halistatin 1
US5328929A (en) Isolation and structure of spongistatin 2, spongistatin 3, spongistatin 4 and spongistatin 6
Pettit et al. Anti neoplastic agents. CCLII. Isolation and structure of Halistatin 2 from the Comoros marine sponge Axinella carteri
Bu et al. New flexible cembrane-type macrocyclic diterpenes as TNF-α inhibitors from the South China Sea soft coral Sarcophyton mililatensis
Tian et al. Microsclerodermins N and O, cytotoxic cyclic peptides containing a p-ethoxyphenyl moiety from a deep-sea marine sponge Pachastrella sp.
Ondeyka et al. Coprophilin: an anticoccidial agent produced by a dung inhabiting fungus
US7626043B2 (en) Antiproliferative activity of the leiodermatolide class of macrolides
CA1338184C (en) Bu-3862t antitumor antibiotic
KR20200029819A (en) Novel compounds from Streptomyces sp. and use thereof
US20020016357A1 (en) Novel discalamide compounds and their use as anti-proliferative agents
Pedradab Isolation and structure elucidation of secondary metabolites from marine sponges and a marine-derived fungus
US5093248A (en) BU-3862T antitumor antibiotic
Yoo Bioactive secondary metabolites from marine algae and study of oxidized anandamide derivatives
WO1995027731A1 (en) Compound ge3
FI80047B (en) FOERFARANDE FOER FRAMSTAELLNING AV REBECCAMYCINDERIVAT.
EP0408336A2 (en) Antitumor antibiotic BU-3285T
Reda Chemical Study on the Bioactive Constituents from Red Sea Marine Organisms
KR0177585B1 (en) Antitumor Substance B E-13793C-producing strain

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 19940903

17Q First examination report despatched

Effective date: 19960111

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

REF Corresponds to:

Ref document number: 166652

Country of ref document: AT

Date of ref document: 19980615

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: R. A. EGLI & CO. PATENTANWAELTE

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69410492

Country of ref document: DE

Date of ref document: 19980702

ITF It: translation for a ep patent filed

Owner name: JACOBACCI & PERANI S.P.A.

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2119077

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 19980730

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19990118

Year of fee payment: 6

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 19990201

Year of fee payment: 6

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 20000131

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20040107

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20040108

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20040113

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20040114

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20040115

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20040119

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20040121

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20040122

Year of fee payment: 11

Ref country code: IE

Payment date: 20040122

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20040123

Year of fee payment: 11

Ref country code: ES

Payment date: 20040123

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20040129

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20040409

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050119

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050119

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050119

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050120

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050131

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050131

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050131

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050719

BERE Be: lapsed

Owner name: ARIZONA *BOARD OF REGENTS

Effective date: 20050131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050802

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050802

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20050119

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050930

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Effective date: 20050719

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20050801

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20050120

BERE Be: lapsed

Owner name: ARIZONA *BOARD OF REGENTS

Effective date: 20050131